EuropeanJournalofPublicHealth,Vol.16,No.2,198–202
(cid:1)TheAuthor2005.PublishedbyOxfordUniversityPressonbehalfoftheEuropeanPublicHealthAssociation.Allrightsreserved.
doi:10.1093/eurpub/cki168AdvanceAccesspublishedonSeptember12,2005
............................................................................................................
Drug-related mortality and its impact on adult
mortality in eight European countries
Anna Maria Bargagli1, Matthew Hickman2, Marina Davoli1, Carlo A. Perucci1,
Patrizia Schifano1, Marcel Buster3, Teresa Brugal4, Julian Vicente5
for the COSMO European Group6
Objective:Toestimatethemortalityratesfromdrug-relateddeathsandothercausesamongproblem
drugusersandpopulationattributableriskofdeathduetoopiateuseineightstudysitesinEurope.
Methods:Opiateuserswererecruited fromdrug treatmentcentresduringtheperiod1990–1998and
deathsfollowedupthroughnationalorlocalmortalityregistries.Gender-specificoverallmortalityrate,
proportion of deaths by cause (drug-related, HIV, other), standardized mortality ratios (SMRs), and
the attributable risk fraction (ARF) were estimated. Results: Crude mortality rates varied from 1 per
100person-yearsintheDublinandLondoncohortsto3.8per100person-yearsinBarcelona.Thehighest
drug-relatedmortalityratewas10per1000person-yearsinBarcelona;therateswere(cid:1)7per1000person-
yearsinDenmark,London,Rome,andVienna,and<3.5per1000person-yearsfortheotherscohorts.
The mortality rate for AIDS was <2 per 1000 person-years in all the cohorts except Lisbon, Rome,
andBarcelona,forwhichitwas(cid:1)6per1000person-years.ThehighestSMRamongmaleswas21.1in
Barcelona,andamongfemalesthehighestSMRswere53.7and37.7inBarcelonaandRome,respectively.
In Denmark the ARF was 5%, whereas it was >10% in all other study sites and 24% in Barcelona.
Conclusion: Cohort mortality studies, especially in combination with estimates ofprevalence, provide
usefulinsightsintotheimpactofopiateuseonmortalityacrossEuropeancountriesandemphasizehow
preventingoverallanddrug-relateddeathsamongopiateuserscansignificantlyimprovethehealthof
thepopulation.
Keywords: drug-relatedmortality,longitudinalstudies,opiateaddiction
............................................................................................................
The advantage of mortality statistics over most surveillance samplesofproblemdrugusersidentifyallcausesofdeathand
systems is that they are invariably complete;1 information measure both the overdose and all cause mortality rate. If
on cause of death can also be obtained, although only on the successful, they offer the opportunity of a full picture of
conditionthatonecanidentifythepopulationonewantstobe drug-related mortality and support the interpretation of
informed about. Although drug poisoning/overdose and drug mortality statistics.3
dependence are key causes of death directly attributable to The occurrence of heroin use and the mortality associated
problem drug use, problem drug users can die from many withitvarybetweengeographicalareas.4–10Ingeneral,theopi-
othercauseswhicharenotreadilyvisibleinroutinepopulation ateoverdosemortalityratewillbehigherinpopulationswitha
mortality statistics because we cannot identify problem drug higherprevalenceofinjectingdruguse.However,otherfactors
users intheregister. Furthermore, any interpretation of drug- may govern the impact of opiate and injecting drug use on
relateddeaths2overtimehastodistinguishbetweenatleasttwo opiate poisoning and all cause mortality, notably HIV preva-
potentialexplanations:changesintheprevalenceofopiateuse lence among injecting drug users (IDUs) and also the average
andinmortalityrisk.Mortalitycohortstudieswhichfollowup age of the cohort and availability of substitution treatment.
Many longitudinal studies show IDUs to have higher overall
............................................................. and cause-specific mortality rates than the general, gender-
1 DepartmentofEpidemiology,ASLRomeE,Rome,Italy andage-matched,population,7,11–13withmeta-analysisestimat-
2 CentreforResearchonDrugsandHealthBehaviour,Social ing that the risk of death among injectors was over 13 times
ScienceandMedicine,ImperialCollegeSchoolofMedicine, higherandthatthedrug-relatedmortalityratewas(cid:1)0.8%per
London,UK annum.14 In this study we estimate the excess of mortality
3 DepartmentofEpidemiology,DocumentationandHealth
among opiate users enrolled in eight European cohorts
Promotion,MunicipalHealthService,Amsterdam,
compared with the general population and the proportion of
TheNetherlands
deaths in the general population that may be attributable to
4 PublicHealthAgency,EpidemiologicService,IMS,Barcelona,
Spain opiateuse.
5 DepartmentofEpidemiology,EuropeanMonitoringCentrefor
DrugsandDrugAddiction,Lisbon,Portugal
Methods
6 COSMO(COhortStudiesonMortalityofOpiateaddicts):
JosephBarry(Ireland),ValeriaBelleudi(Italy),SheilaBird(UK),
The study population included eight cohorts of opiate users
DanielaDeAngelis(UK),FilipaFerrazdeOliveira(Portugal),
PaulGriffith(EMCDDA),LeneHaastrup(Denmark),Eva collected by the European Monitoring Centre for Drugs and
Hammerby(Denmark),GordonHay(Scotland),Axel DrugAddiction(EMCDDA)workinggrouponcohortmortal-
Heinemann(Germany),SharonHutchinson(Scotland), itystudiesamongopiateaddicts.Allcohortsconsistedofopiate
DominiqueLopez(France),LouiseMullen(Ireland), users aged 15–69 years entering treatment during the period
DanieleRisser(Austria),AlessandraSperati(Italy),
1990–1999andfollowedupusingacomparablemethodology.
ColinTaylor(EMCDDA)
Deaths among the subjects were traced by linking the cohorts
Correspondence:AnnaMariaBargagli,Departmentof
with national or municipal registers. A more detailed descrip-
Epidemiology,ASLRomeE,ViadiSantaCostanza53,
00198Roma,Italy,tel:þ390683060402,fax:þ390683060463, tion of the different cohorts and the methodology has been
e-mail:bargagli@asplazio.it published elsewhere.15 Participant study sites were selected on
Downloaded
from
http://eurpub.oxfordjournals.org/
by
guest
on
November
14,
2015
Drug-relatedmortality 199
the basis of the availability of basic information on patients Estimates of the prevalence of opiate use were obtained from
entering treatment and access to population and/or mortality the literature and EMCDDA sponsored studies.18–22 Credible
registries.Subjectscontributedperson-yearsatriskuptotheage estimates for Lisbon were not available, so the ARF was not
of 69 years, the end of the study period, or date of death, calculated.
whichever came first. Causes of death where available were
retrieved according to the following selection of ICD-IX and
Results
ICD-Xcodes:
Drug-relateddeaths:292;304.0–.9;305.2–.9;965.0–.9;969.0–.9; The proportion of males in the cohorts ranged from 69% in
E850–E858; E980.0-5;E980.9; E950.0-.5;E950.9; E962; Viennato82%inRome,andtheaverageageatrecruitmentwas
F11–F16;F18–F19;X40–X44,X49;Y10–Y14,Y19;X60–X64; 25–29yearsinsixofthecohortsand>30yearsintheDanishand
X85. Dutch cohorts. Table 1 shows the number of subjects in the
HIV-relateddeaths:042.0–044.9;279.1;279.5;279.8;B20–B24. cohort, the study period, and crude death rates overall and
among males and females aged 15–69 years. The mortality
Theremainingcauseswereclassifiedas‘other’.
rate varied from just over 1 per 100 person-years in Dublin
Standardized mortality ratios (SMRs) were calculated in
and London to 2 per 100 person-years in Rome and 3.8 per
order to estimate the overall mortality excess among opiate
100 person-years in the Barcelona cohort (i.e. nearly 1 in
userscomparedwiththegeneralpopulationofthesameageand
25 cohort subjects dying per year). Death rates for males and
gender.SMRswerecalculatedseparatelyformalesandfemales,
femalesweresimilarinthecohortsfromAmsterdam,Denmark,
with the expected number of deaths in the cohort generated
Barcelona,Lisbon,andRome,whereasinDublin,Vienna,and
from the mortality rate of the individual country by 5-year
London the death rate was 2–3-fold lower among females in
agegroup(fortheyearinthemiddleofthefollow-upperiod).16
the cohorts than among male opiate users (i.e. 0.5–0.8 per
Two-sided95%confidenceintervalsforSMRswerebasedonthe
100person-yearscomparedwith1.3–1.6per100person-years).
Poisson distribution. The attributable risk fraction (ARF) was
Table2showsthemortalityratesandproportionofdeathsby
calculatedasfollows(foradultsaged15–49yearsbecausepreva-
cause.Theproportionofdrug-relateddeathsvariesfrom(cid:1)7%
lenceestimateswereavailablethis agegroup): inLisbonto60%intheLondoncohort.Thehighestmortality
ARF¼P ðSMR(cid:2)1Þ=(cid:1) P ðSMR(cid:2)1Þþ1(cid:2) :17 rate from fatal overdose was 13 per 1000 person-years in
opiate opiate Barcelona, compared with (cid:1)7 per 1000 person-years in
Table1 Numberofsubjectsenrolledintheeightcohortsandcrudedeathrates(per1000person-years)
Studysite Studyperiod Numberofsubjects Person-years Numberofdeaths Crudedeathrate
Overall Males Females
Amsterdam 1996–2002 2575 10576.31 174 16.45 16.72 15.39
..............................................................................................................................
Barcelona 1992–2001 5037 30237.06 1137 37.60 38.94 33.38
..............................................................................................................................
Denmark 1996–2002 8808 40317.80 701 17.39 18.33 14.78
..............................................................................................................................
Dublin 1994–1997 5285 10345.27 114 11.02 13.17 5.30 ..............................................................................................................................
Lisbon 1992–2003 3275 28619.70 440 15.37 16.13 12.35
..............................................................................................................................
London 1997–2001 881 2850.39 35 12.28 13.82 7.97
..............................................................................................................................
Rome 1992–1997 5924 21248.39 425 20.00 19.92 20.37
..............................................................................................................................
Vienna 1990–1998 4150 14834.62 195 13.14 16.41 6.01
Agerange15–69yearsforbothcalculationofperson-yearsatriskandnumberofdeaths
Table2 Numberandproportionofdeaths,andmortalityratebycause,allages(15–69years),bycohort
Studysite Drug-relateddeaths AIDSdeaths Othercauses Missingcauses
n % Cruderate/ n % Cruderate/ n % Cruderate/ n % Cruderate/
1000 1000 1000 1000
Amsterdama — — —
..............................................................................................................................
Barcelona 392 34.5 12.96 421 37.0 13.9 280 24.6 9.3 44 3.9 1.46
..............................................................................................................................
Denmark 285 40.7 7.07 17 2.4 0.42 169 24.1 4.19 230 32.8 5.70
..............................................................................................................................
Dublin 32 28.1 3.09 24 21.1 2.32 54 47.4 5.22 4 3.5 0.39
..............................................................................................................................
Lisbon 32 7.3 1.12 179 40.7 6.25 181 41.1 6.32 48 10.9 1.68
..............................................................................................................................
London 21 60.0 7.37 0 0.0 0.00 10 28.6 3.51 4 11.4 1.40
..............................................................................................................................
Rome 141 33.2 6.64 135 31.8 6.35 142 33.4 6.68 7 1.7 0.33
..............................................................................................................................
Vienna 98 50.3 6.61 37 19.0 2.49 60 30.8 4.04 0 0 0
a:Noinformationoncausesofdeathavailable
Downloaded
from
http://eurpub.oxfordjournals.org/
by
guest
on
November
14,
2015
200 EuropeanJournalofPublicHealth
Denmark, London, Rome, and Vienna. No deaths from AIDS Discussion
were found in the cohort recruited in London, while the pro-
portion of AIDS deaths varied considerably across the other Thisdescriptivestudyemphasizesthepublichealthimportance
cohorts,from(cid:1)2%inDenmarkto41%inLisbon,withsimilar ofdrug-relatedmortality,thescaleofriskexperiencedbyopiate
deathratesinRomeandLisbonof(cid:1)6per1000.Severalofthe users (mostly heroin injectors), and the potential impact of
cohorts had substantial numbers of deaths with missing or opiate use on the health of the adult population, especially in
unascertained causes, e.g. in Lisbon, London, and Denmark citiesinEurope.Theevidenceisclear:ifwemanagetoprevent
>10%weremissinginformation oncauseofdeath. opiateuse,transmissionofHIVamongIDUs,andfataloverdose
Table3showstheSMRcomparingthemortalityrateinthe we will improve significantly the overallhealth ofthe popula-
cohortwiththegeneralpopulation.Infouroftheeightsitesthe tion.Thefindingsalsounderlinethevalueofmortalitycohort
mortality rate was 10 times higher than in the general popu- studies. Further, the difference between the sites suggests that
lation. In Barcelona the SMR was 21.1 in males and 53.7 in thereisunlikelytobeanystandardorinherentdrugmortality
females; in Rome female opiate users were nearly 40 times rateorSMRamongproblemdrugusers.Nevertheless,mostof
more likely to die than females in the general population. In thecohortestimatessuggestedahighermortalityrateandSMR
LisbontheSMRamongmaleswasjustover6timeshigherthan than an earlier meta-analysis14—i.e. that the annual mortality
in the general population, and in Vienna the SMR among rateofopiateusersis>1in100andcouldbeashighas3.7per
females was just over 10 times higher. Given that death rates 100, withan SMRranging from 6 to 54 and 10–20% of adult
intheadultpopulationarehigherinmalesthaninfemales,the mortality at ages 15–49 years attributable to opiate use. In
largest differences in SMR between males and females were Barcelona nearly one in four deaths among young adults are
observed for those cohorts where the mortality rate of opiate potentially due to opiate use. The drug-related mortality rate
usersbygenderwassimilar(seetable1),whereascohortswith acrossthesiteswasmoreconsistent,rangingfrom0.7to1%in
higher death rates among male opiate users reported similar fiveofthesites.However,thelowerrate,representedinLisbon,
SMRsformalesandfemales. may reflect problems with the coding/certification of deaths.
Table 4 shows estimates of the ARF (i.e. the proportion of Part of the variation in overall mortality between the cohorts
deaths in the general population that may be attributable to reflects the uneven distribution of HIV infection in Europe,
opiate use if the total surplus of deaths in the cohort were with high death rates and SMRs found in Southern European
causally related to opiate use). Denmark is the only country- countries wheretheprevalenceofHIValsoishigher.3
levelcohort;ithasalowprevalenceofopiateuseandtherefore Although they illustrate the scale of the problem, the study
<5%ofadultmortalityatages15–49attributabletoopiateuse. estimatesneedtobetreatedcautiously, andouranalyses were
IncontrastalmostoneinfouradultdeathsinBarcelonacouldbe limited by a lack of information on the generalizability of
a consequence of opiate use. In the other study sites the ARF the cohorts to all opiate users and IDUs in the respective
rangedfrom 10to17%. sites. There are several potential biases that could lead to an
Table3 Allcausesstandardizedmortalityratios(SMRs)and95%confidenceintervals(95%CI),allages(15–69years),bycohort,
1990–2000
Studysite Observed Expected SMR15–69(95%CI)
Males Females Males Females Males Females
Amsterdam 141 33 19.7 2.7 7.2(6.1–8.4) 12.2(8.7–17.2)
..............................................................................................................................
Barcelona 894 243 42.4 4.5 21.1(19.8–22.5) 53.7(47.4–60.9)
..............................................................................................................................
Denmark 543 158 68.4 15.2 7.9(7.3–8.6) 10.4(8.9–12.1)
..............................................................................................................................
Dublin 99 15 9.2 1.3 10.7(8.8–13.1) 11.4(6.9–18.9)
..............................................................................................................................
Lisbon 369 71 58.3 4.3 6.3(5.7–7.0) 16.7(13.2–21.0)
..............................................................................................................................
London 29 6 2.4 0.4 12.2(8.5–17.6) 15.8(7.1–35.1)
..............................................................................................................................
Rome 347 78 25.5 2.1 13.6(12.2–15.1) 37.7(30.2–47.1)
..............................................................................................................................
Vienna 167 28 16.8 2.7 9.9(8.5–11.6) 10.2(7.1–14.8)
Table4 Attributableriskfraction(ARF)ofallcausemortalitybyopiateuse,ages15–49years,bycohort
Studysite Population Estimatednumber Prevalenceof Standardizedmortality ARF(%) Studyperiod
ofopiateusers opiateuse(%) ratio(15–49years)
Amsterdam 369000 5000 1.4 10.1 10.9 1996–2002
..............................................................................................................................
Barcelona 746318 9176 1.2 25.6 22.8 1992–2001
..............................................................................................................................
Denmark 2553000 14000 0.5 9.2 4.3 1996–2002
..............................................................................................................................
Dublin 588000 12250 2.1 10.9 17.0 1994–1997
..............................................................................................................................
London 3919000 62000 1.6 13.6 16.6 1997–2001
..............................................................................................................................
Rome 1317000 14500 1.1 15.4 13.7 1992–1997
..............................................................................................................................
Vienna 786000 10200 1.3 9.8 10.3 1990–1998
Downloaded
from
http://eurpub.oxfordjournals.org/
by
guest
on
November
14,
2015
Drug-relatedmortality 201
under-oroverestimateofthedifferentmortalitymeasures.First, drug users in Europe. The authors thank the EMCDDA for
the mortality rates observed among the cohorts may not be supportingandfacilitatingtheworkofthestudygroup.
representative of the rates of the total population of opiate
users.Thestudypopulationswererecruitedthroughtreatment
centres, which under-represent recent opiate users. Moreover, Key points
different criteria to enter treatment may result in differential
selection across countries. Cohort mortality may be higher if (cid:3) The study estimates mortality rates of opiate users
treatmentattractsthosedruguserswiththemostseriousmor- in Amsterdam, Barcelona, Denmark, Dublin, Lisbon,
bidity or it may be lower (immediately after recruitment) London,Rome,andVienna.
becauseoftheprotective effectoftreatment. (cid:3) Mortality rates range from 1 per 100 person-years
Second,prevalenceestimatesandthusARFarebasedonthe in Dublin and London to 3.8 per 100 in Barcelona
official population. Larger cities, however, may attract drug andare6–54timeshigherthanexpectedinthegeneral
userswhodonotbelongtotheregisteredpopulationofthatcity. population.
Third,notallexcessmortalityislikelytobecausedbyopiate (cid:3) 10–20% of adult mortality at ages 15–49 years is
use:strongriskfactorsformortalitysuchasdeprivation,smok- attributable toopiateuse.
ing,drinking,andotherriskybehaviourarestronglyassociated (cid:3) Public health interventions targeted towards opiate
withopiateuse;controlled forthesemightreducetheSMR. users/IDUs may produce a major effect on the health
Fourth, the SMR underestimates the risk ratio based on ofthegeneral populationoverall.
thegeneral population ratherthan anon-opiate using cohort. (cid:3) Investment in mortality cohort studies among drug
However, it must be considered that because we use national usersisrequiredtomonitortemporalandgeographical
reference ratesratherthan localonesthis effectwillbesmall. trendsinoverallandcause-specific mortality.
In addition to potential methodological issues, the infor-
mation about the cohorts is too limited to draw conclusions
concerningdrugpolicy.Dataoninjectingstatusanddrugpro-
References
filewerenotcollectedfromenoughofthesubjectsinthecohorts
totestwhetherthesecouldexplaindifferencesinthemortality
1 DollR.Progressagainstcancer:anepidemiologicalassessment. ratebetweenthecohorts.Moreover,althoughallsubjectswere
AmJEpidemiol1991;7:675–8.
selectedfromtreatmentsitestheyalsodifferacrosssitesinterms
2 EuropeanMonitoringCentreforDrugsandDrugAddiction.Standard
of age distribution, years of follow-up, and length of time in
protocolfortheEUMemberStatestocollectdataandreportfiguresfortheKey
contactwithtreatmentservices,allofwhichcanhaveanimpact
IndicatorDrug-RelatedDeathsbytheStandardReitoxtables.EMCDDA
on the risk of death.23–26 Thus, any differences in the distri-
projectCT.02.P1.05.EMCDDAScientificReport.Luxembourg:
bution ofthesefactors between subjectsinthecohortandthe
EMCDDA,2002.
underlyingpopulation wouldadd biastothefindings.
3 EuropeanMonitoringCentreforDrugsandDrugAddiction.AnnualReport
IdeallytheARFwouldbeestimatedseparatelyformalesand
2003:thestateofthedrugsproblemintheEuropeanUnionandNorway;
females;however,theprevalenceestimateswerenotsufficiently availableathttp://www.emcdda.eu.int.Luxemburg:EMCDDA,2003.
robust and we did not want to compound theuncertainty. In
4 CherubinCE,SapiraJD.Themedicalcomplicationsofdrugaddictionand
general, the ARF would be larger for males than for females, themedicalassessmentoftheintravenousdruguser:25yearslater.
given that it is likely that about three-quarters of opiate users AnnInternMed1993;119:1017–28.
would be male. Finally, the current cohorts include too many 5 delaFuenteL,BarrioG,VicenteJ,etal.Theimpactofdrug-relateddeaths
unknowns to permit a comparative assessment of the risk of onmortalityamongyoungadultsinMadrid.AmJPublicHealth
death among countries. For instance, do the sites with higher 1995;85:102–5.
mortality rates indicate inequalities in provision of specialist 6 SelwynPA.Injectiondruguse,mortality,andtheAIDSepidemic.
drugtreatmentorotherharmreduction/prevention initiatives AmJPublicHealth1991;81:1247–9.
and/orgreater environmentalrisk? 7 FrischerM,Goldberg,D,RahmanM,BerneyL.Mortalityandsurvival
Jointevaluationofthemortalityrates,SMRs,andprevalence amongacohortofdruginjectorsinGlasgow,1982–1994.Addiction
of opiate use, however, could provide useful insights into the 1997;92:419–27.
impactofopiateuseonmortalityacrossEuropeancountriesand 8 Ortı`RM,Domingo-SalvanyA,MunozA,etal.Mortalitytrendsinacohort
should be a goal of future surveillance of drug-related deaths. ofopiateaddicts,Catalonia,Spain.IntJEpidemiol1996;25:545–53.
OurdatacorroboratereportsthatinmanyEuropeancountries 9 BargagliAM,SperatiA,DavoliM,etal.Mortalityamongproblemdrug
drugusers haveahighmortalityriskofdeathfrominfectious usersinRome:an18yearsfollow-upstudy1980–1997.Addiction
diseases,AIDS,drug-relateddeaths, andviolence.27–30Incon- 2001;96:1455–63.
clusion, our results suggest that public health interventions 10 WarhenAC,BrandtL,AllebeckP.Hasmortalityindrugaddictsincreased?
targeted towards opiate users/IDUs, though a comparatively AcomparisonbetweentwohospitalisedcohortsinStockholm.
smallproportionofthepopulation,mayproduceamajoreffect IntJEpidemiol1997;26:1219–26.
on the health of the general population overall, especially in 11 Engstro¨mA,AdamssonC,AllebeckP,RydbergU.Mortalityinpatientswith
cities.Moreover,weurgeinvestmentinstandardizedmortality substanceabuse:afollow-upinStockolmCounty,1973–1984.IntJAddict
1991;26:91–106.
cohortsofopiateusersacrossEuropeandreliableestimatesof
the prevalence of opiate use. These instruments will enable a 12 QuaglioG,TalaminiG,LechiA,etal.Studyof2708heroin-relateddeaths
innorth-easternItaly1985–98toestablishthemaincausesofdeath.
clearer comparison among countries of the scale of different
Addiction2001;96:1127–37.
causes of death among problem drug users in order both to
13 HickmanM,CarnwathZ,MaddenP,etal.Drug-relatedmortalityandfatal
monitor this important public health problem and to identify
overdoserisk:pilotcohortstudyofheroinusersrecruitedfromspecialist
sites which have reduced the risk of death and improved the
drugtreatmentsitesinLondon.JUrbanHealth2003;80:274–87.
healthofthepopulation.
14 HulseGK,EnglishDR,MilneCD,HolmanCD.Thequantificationof
mortalityresultingfromtheregularuseofillicitopiates.Addiction
1999;94:221–9.
Acknowledgements 15 EuropeanMonitoringCentreforDrugsandDrugAddiction.Mortalityof
drugusersintheEU:co-ordinationofimplementationofnewcohortstudies,
This study has been carried out within the EMCDDA project follow-upandanalysisofexistingcohortsanddevelopmentofnewmethodsand
aimedatpromotingcohortstudiesonthemortalityofproblem outputs.EMCDDAScientificReport.Luxembourg:EMCDDA,2002.
Downloaded
from
http://eurpub.oxfordjournals.org/
by
guest
on
November
14,
2015
202 EuropeanJournalofPublicHealth
16 UnitedNations.Demographicyearbook1999.NewYork:UnitedNations, 24 McLellanAT,LuborskyL,O’BrienCP.Alcoholanddrugabusetreatmentin
StatisticsDivision,2001. threedifferentpopulations:isthereimprovementandisitpredictable?
17 EnglishDR,HolmanCD,MilneE,etal.Thequantificationofdrug-caused AmJDrugAlcoholAbuse1986;12:101–20.
morbidityandmortalityinAustralia1995.Canberra:Commonwealth 25 StrainEC,StizerML,BigelowGE.Earlytreatmenttimecourseof
DepartmentofHumanServicesandHealth,1995. depressivesymptomsinopiateaddicts.JNervMentDis
18 HickmanM,HigginsV,HopeV,etal.InjectingdruguseinBrighton, 1991;179:215–21.
Liverpool,andLondon:bestestimatesofprevalenceandcoverageofpublic 26 GalaiN,SafaeianM,VlahovD,etal.Longitudinalpatternsofdruginjection
healthindicators.JEpidemiolCommunityHealth2004;58:766–71. behaviourintheALIVEStudycohort,1988–2000:descriptionand
19 BrugalMT,DomingoSalvanyA,etal.Asmallareaanalysisestimating determinants.AmJEpidemiol2003;158:695–704.
theprevalenceofaddictiontoopiatesinBarcelona,1993.JEpidemiol
27 RobertsonJR,RonaldPJ,RaabJM,etal.Deaths,HIVinfection,abstinence,
CommunityHealth1999;53:488–94. andotheroutcomesinacohortofinjectingdrugusersfollowedup
20 ComiskeyCM,BarryJM.Acapture-recapturestudyoftheprevalenceand for10years.BrMedJ1994;309:369–72.
implicationsofopiateuseinDublin.EurJPublicHealth2001;11:198–200.
28 OppenheimerE,TobuttC,TaylorC,AndrewT.Deathandsurvivalina
21 BusterMC,vanBrusselGH,vandenBrinkW.Estimatingthenumberof cohortofheroinaddictsfromLondonclinics:a22-yearfollow-upstudy.
opiateusersinAmsterdambycapture-recapture:theimportanceofcase Addiction1994;89:1299–1308.
definition.EurJEpidemiol2001;17:935–42.
29 MarzukPM,TardiffK,LeonAC,etal.Fatalinjuriesaftercocaineuse
22 EuropeanMonitoringCentreforDrugsandDrugAddiction.National
asaleadingcauseofdeathamongyoungadultsinNewYorkCity.
prevalenceestimatesofproblemdruguseintheEuropeanUnion,1995–2000.
NEnglJMed1995;332:1753–7.
EMCDDAprojectCT.00.RTX.23,Finalreport,vol.I:Results.Luxembourg:
30 Sanchez-CarbonellX,SeusL.Ten-yearsurvivalanalysisofa
EMCDDA,2002.
cohortofheroinaddictsinCatalonia:theEMETYSTproject.
23 vanHaastrechtHJA,vanAmeijdenEJC,vandenHoekJAR,etal.Predictors
Addiction2000;95:941–8.
ofmortalityintheAmsterdamcohortofhumanimmunodeficiency
virus(HIV)-positiveandHIV-negativedrugusers.AmJEpidemiol
Received8September2004,accepted29June2005
1996;143:380–91.
Downloaded
from
http://eurpub.oxfordjournals.org/
by
guest
on
November
14,
2015
